Enzychem Lifesciences
Company Details
Status: Public
Employees: 11-50
Location:
Seoul, Korea
Type:
sample
Technology:
sample
sample
About: Enzychem Lifesciences, Corp. (KOSDAQ:183490) is a global biopharmaceutical company headquartered in Seoul, Korea, which is dedicated to developing new drugs and APIs (Active Pharmaceutical Ingredients). Since its foundation in 1999, Enzychem Lifesciences has been striving to develop new and innovative treatments capable of addressing unmet medical needs with R&D-driven approaches under its grand mission of "Saving Human Lives by Overcoming Unmet Medical Needs"
EC-18, the lead compound of Enzychem Lifesciences, is an immune modulator driven from deer antler that has the potential to be used for a variety of indications. At present, three clinical trials for different indications are being conducted; Chemotherapy Induced Neutropenia (CIN), Chemoradiation Induced Oral Mucositis (CRIOM), and Acute Radiation Syndrome (ARS). In order to facilitate the clinical trial process, Enzychem launched a US operation office in New Jersey on June 28, 2018.
Currently, Enzychem Lifesciences is one of the fastest growing life science companies in KOSDAQ Stock Exchange in terms of market capitalization. The company is headquartered in Seoul, Korea.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Enzychem Lifesciences | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.